SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

The Invesco QQQ Trust is experiencing significant volatility as investors weigh calls from AI executives for a development slowdown against strong market-wide buying pressure. The conversation is dominated by uncertainty surrounding upcoming Federal Reserve rate hike expectations and rising Treasury yields, with community sentiment remaining sharply divided between those betting on a market correction and those anticipating a continued rally.

XPeng, Inc. is a global Physical AI company, dedicated to bringing artificial intelligence into the physical world to reshape future mobility and smart living. The firm developed a full-stack Physical AI architecture spanning Turing AI chips, world foundation models, and highly integrated software and hardware applications. The product portfolios of smart EVs, robotaxis, and humanoid robots, advancing the deployment of Physical AI at scale. It manufacturing, sales, and services, drives continuous technological innovation and fosters an open physical AI ecosystem, making life smarter, safer, and better for users worldwide. The company was founded by Xiao Peng He, Heng Xia, and Tao He in 2015 and is headquartered in Guangzhou, China.

XPeng Inc - ADR

XPeng is experiencing significant volatility and downward pressure as investors weigh recent reports of management stake adjustments and mixed delivery data against the company's long-term potential in robotics, AI-driven autonomous driving, and international expansion. While some traders express frustration with the stock's persistent decline, others view current valuation levels as an opportunity to accumulate, citing the strategic value of the company's robotics division and its partnership with Volkswagen.

iShares Trust - iShares 20+ Year Treasury Bond ETF

iShares 20+ Year Treasury Bond ETF

TLT is trending as traders debate the likelihood of an interest rate hike in the upcoming Federal Reserve meeting, fueled by persistent inflation, rising Treasury yields, and escalating oil prices. Community sentiment is deeply polarized, with many expecting further downside for bonds due to structural debt concerns, while others view current price levels as a potential long-term value opportunity.

Clover Health Investments Corp. is a physician enablement technology company, which engages in the provision of Medicare Advantage plans in the United States. Its strategy is powered by its proprietary software platform, Clover Assistant, which aggregates patient data from across the healthcare ecosystem to support clinical decision-making and improve health outcomes through the early identification and management of chronic diseases. The company offers PPO and HMO Medicare Advantage plans in several states, with a differentiated focus on its flagship wide-network, high-choice PPO plans. The company was founded by Vivek Garipalli and Andrew Toy on July 17, 2014 and is headquartered in Wilmington, DE.

Clover Health Investments Corp - Ordinary Shares - Class A

Clover Health Investments Corp

Clover Health is trending as traders speculate on a potential partnership with Humana, fueled by retail discovery of job postings that list Clover's Counterpart Health as a vendor. While the community is highly bullish on the validation this would provide for Clover's technology, others note that no official announcement has been made and that the stock has historically struggled to sustain gains.

ProShares Trust II - ProShares Ultra VIX Short-Term Futures ETF 1.5x Shares

ProShares Ultra VIX Short-Term Futures ETF

The community is debating the effectiveness of the ETF as a hedging tool amid geopolitical tensions and market volatility, with many traders expressing frustration over its structural decay and perceived manipulation. While some remain bullish on a potential spike, others emphasize that its design inherently leads to losses over time, favoring shorting strategies instead.

SPDR S&P 500 ETF TRUST - SPDR S&P 500 ETF Trust

The primary catalyst driving market sentiment is widespread concern over rising Treasury yields, which recently crossed 5%, alongside uncertainty surrounding the upcoming Federal Reserve policy decision where a rate hike is largely expected. Traders are also actively debating the implications of industry-wide calls to moderate the pace of AI development, leading to notable sector rotation between chipmakers and software equities.

AppLovin Corp. engages in the development and operation of a mobile marketing platform. It offers AppDiscovery, MAX, Adjust, and SparkLabs. Its software-based platform caters to mobile application developers to improve the marketing and monetization of applications. The company was founded by Andrew Karam, John Krystynak, and Adam Foroughi in 2011 and is headquartered in Palo Alto, CA.

Applovin Corp - Ordinary Shares - Class A

Applovin Corp

AppLovin shares are experiencing significant volatility and fragmented sentiment, with traders debating whether the stock is being systematically manipulated by market makers to accumulate shares or is simply struggling against broader macroeconomic pressures. While many investors remain bullish due to strong earnings and e-commerce growth prospects, others are frustrated by the lack of upward momentum and are closely watching key technical support levels.

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

The community is primarily focused on the surge in crude oil prices driven by escalating geopolitical tensions in the Middle East, particularly reports of attacks on Saudi oil infrastructure and shipping in the Strait of Hormuz. Traders are actively debating whether these disruptions will push the fund significantly higher toward a potential breakout or if the rally is overextended and vulnerable to a sharp reversal.

VanEck ETF Trust - VanEck Gold Miners ETF

VanEck Gold Miners ETF

The GDX ETF is trending due to significant inflows into gold-mining stocks, as traders position for precious metals to act as a safe-haven hedge against economic uncertainty, currency debasement, and rising national debt. While market participants are divided on the technical sustainability of the current rally—with some anticipating a pullback and others citing a long-term breakout—the sector continues to draw heavy retail and institutional interest.

Forgent Power Solutions, Inc. is a holding company, which engages in the design and manufacture of electrical distribution equipment used in data centers, power grid, and energy-intensive industrial facilities. It also offers powertrain solutions and standard and custom products. The company was founded on July 21, 2025 and is headquartered in Dayton, MN.

Forgent Power Solutions Inc. - Ordinary Shares - Class A

Forgent Power Solutions Inc.

Forgent Power Solutions is receiving significant attention as investors anticipate growth driven by data center electrification and power infrastructure demand, following a recent earnings report that highlighted a substantial backlog. While some traders express concern regarding institutional selling and recent secondary offerings, many view the current price action as an accumulation opportunity based on the company's long-term growth thesis.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Sagimet Biosciences (SGMT) Attracts Attention After Russel Indexes Inclusion

Sagimet Biosciences (SGMT) Attracts Attention After Russel Indexes Inclusion...

Here's Why Sagimet Biosciences Inc. (SGMT) Could be Great Choice for a Bottom Fisher

After losing some value lately, a hammer chart pattern has been formed for Sagimet Biosciences Inc. (SGMT), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

Wall Street Analysts Believe Sagimet Biosciences Inc. (SGMT) Could Rally 298.5%: Here's is How to Trade

The mean of analysts' price targets for Sagimet Biosciences Inc. (SGMT) points to a 298.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Sagimet Biosciences Inc. (SGMT) is a Great Momentum Stock: Should You Buy?

Does Sagimet Biosciences Inc. (SGMT) have what it takes to be a top stock pick for momentum investors? Let's find out.

Does Sagimet Biosciences Inc. (SGMT) Have the Potential to Rally 241.77% as Wall Street Analysts Expect?

The mean of analysts' price targets for Sagimet Biosciences Inc. (SGMT) points to a 241.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Canaccord Genuity Group Raises Sagimet Biosciences (NASDAQ:SGMT) Price Target to $49.00

Canaccord Genuity Group raised their target price on Sagimet Biosciences from $28.00 to $49.00 and gave the stock a 'buy' rating in a research note on Monday...

Sagimet Biosciences Targets Acne, Plans U.S. Phase III for Denifanstat After $175M Raise

Sagimet Biosciences (NASDAQ:SGMT) said it is sharpening its strategic focus on developing differentiated therapies for patients with moderate to severe acne, with plans to advance its lead fatty acid...

Guggenheim Lowers Sagimet Biosciences (NASDAQ:SGMT) Price Target to $25.00

Guggenheim cut their target price on Sagimet Biosciences from $27.00 to $25.00 and set a "buy" rating on the stock in a research note on Wednesday...

Why Is Sagimet Biosciences Stock Trading Higher On Monday?

Sagimet shares surge as Phase 3 acne trial plans and $175M offering fund pipeline through 2028, with technicals showing strong momentum.read more...

Why Sagimet Biosciences Stock Is Soaring Today

Key PointsSagimet Biosciences is developing a handful of drugs, but its priority is acne therapies...

Sagimet Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapeutics for the treatment of infectious diseases. Its lead drug candidate, denifanstat, is an oral, once-daily pill and selective fatty acid synthase (FASN) inhibitor in development for the treatment of nonalcoholic steatohepatitis (NASH). The company was founded by Urs F. Greber, Ari Helenius, and Lucas Pelkmans on December 19, 2006 and is headquartered in San Mateo, CA.

Sagimet Biosciences Inc - Ordinary Shares - Series A

SGMT Stock Surged 40% And Breached 200-DMA For The First Time In Nearly 3 Months – What’s Got Retail Buzzing?

Equity

Bearish Sentiment

50bps hike

25bps hike

No change

25bps cut

The Federal Reserve's September FOMC meeting concludes Wednesday, September 16, with a rate decision due at 2:00 PM ET, following Tuesday's CPI report that showed inflation still running above the Fed's 2% target. What do you think the Fed decides at this week's FOMC meeting? Vote and explain your reasoning in the comments.

The Fed&#39;s rate decision comes Wednesday at 2PM ET. What do you think happens?

Stocktwits

The Fed's rate decision comes Wednesday at 2PM ET. What do you think happens?

Feed

News

Sentiment

Earnings

Fundamentals

Info

SGMT Sagimet Biosciences Inc

Fundamentals

Latest SGMT News